Efgitasialase Alfa

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Approval Year

Substance Class	Protein Created by `admin` on `Wed Apr 02 13:13:50 GMT 2025` Edited by `admin` on `Wed Apr 02 13:13:50 GMT 2025`
Protein Type	FC FUSION PROTEIN
Protein Sub Type	IGG1
Sequence Origin	HUMAN
Sequence Type	COMPLETE
Record UNII	WT5G35J9KU
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

Efgitasialase Alfa

Official Name

English

Human neuraminidase 2 [1-aspartic acid,6-tyrosine,62-glycine,93-glutamic acid,187-lysine,332-alanine] fusion protein with immunoglobulin G1 (human ?1-chain C region C-terminal fragment), dimer

Preferred Name

English

human sialidase-2 (N-acetyl-alpha-neuraminidase 2, exo-alphasialidase, cytosolic sialidase, EC:3.2.1.18) (1-380), variant (M1>D, V<sup>6</sup>>Y, P<sup>62</sup>>G, A<sup>93</sup>>E, I<sup>187</sup>>K, C<sup>332</sup>>A) fused to an Fc fragment of human i

Common Name

English

efgitasialase alfa [INN]

Common Name

English

Code System Code Type Description

INN

13129

Created by admin on Wed Apr 02 13:13:50 GMT 2025 , Edited by admin on Wed Apr 02 13:13:50 GMT 2025

PRIMARY

CAS

2891502-37-5

Created by admin on Wed Apr 02 13:13:50 GMT 2025 , Edited by admin on Wed Apr 02 13:13:50 GMT 2025

PRIMARY

FDA UNII

WT5G35J9KU

Created by admin on Wed Apr 02 13:13:50 GMT 2025 , Edited by admin on Wed Apr 02 13:13:50 GMT 2025

PRIMARY

NCI_THESAURUS

C187111

Created by admin on Wed Apr 02 13:13:50 GMT 2025 , Edited by admin on Wed Apr 02 13:13:50 GMT 2025

PRIMARY

SMS_ID

300000057007

Created by admin on Wed Apr 02 13:13:50 GMT 2025 , Edited by admin on Wed Apr 02 13:13:50 GMT 2025

PRIMARY

From	To
2_532	2_590
2_426	2_486
2_196	2_219
2_88	2_164
1_532	1_590
1_426	1_486
1_394	2_394
1_391	2_391
1_196	1_219
1_88	1_164

Glycosylation Type

MAMMALIAN

Glycosylation Link Type	Site
N	1_120
N	1_462
N	2_120
N	2_462

Related Record Type Details


					WT5G35J9KU

Efgitasialase Alfa

ACTIVE MOIETY

Comments:

antineoplastic

Amount:

Structural Modifications

Modification Type	Location Site	Location Type	Residue Modified	Extent	Fragment Name	Fragment Approval
AMINO ACID REMOVAL	[1_612] [2_612]	C-TERMINUS	K	Amount:	LYSINE	K3Z4F929H6

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
Molecular Formula	CHEMICAL
MOL_WEIGHT:NUMBER(CALCULATED)	CHEMICAL